

*林永昌醫師

所有發表期刊論文、演講及專書

1. **Lin YC**, Chang HK, Sun CF, Shih LY: Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown origin. *South Med J* 88: 683-687, 1995. (SCI)
2. **Lin YC**, Kedelka AP, Tresukosol D, Malpica A, Carrasco CH, Lawrence DD, Collier RE, Munoz A, Delcos L, Kavanagh JJ, Edwards CL: Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy. *Gynaecol Oncol* 58: 262-256, 1995. (SCI)
3. **Lin YC**, Kuldeka AP, Larences D, Verschraegen CF, Kanavagh JJ, Edwards CL, Mante R, Freedman RS: Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma. *Eur J Gynaec Oncol* 17:480-483, 1996.
4. Chen JS, Jan YY, **Lin YC**, Wang HM, Chang WC, Liao CT: Weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with biliary tract carcinomas. *Anti-Cancer Drugs* 9: 393-397, 1998. (SCI)
5. Chen MF, Chen WC, Leung WM, Chang PL, Chu SH, Chuang CK, Liao CC, **Lin YC**, Wu JD, Hong JH: The treatment of prostate cancer by conventional radiation therapy: a 14 years experience in Chang Gung Memorial Hospital. *Therapeut Radiol Oncol* 5:233-243, 1998.
6. Liao CC, Wang HM, Wang CH, Yang TS, Chen JS, Chang HK, **Lin YC**, Liao SJ, Yeh CT: Risk of transient hyperammonemia encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. *Anti-Cancer Drugs* 10: 275-281, 1999.(SCI)
7. Chen JS, Liu HE, Wang CH, Yang TS, Wang MH, Liao CH, Chang WH, **Lin YC**: Weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced gastric cancer. *Anti-Cancer Drugs*, 10: 355-359, 1999. (SCI)(corresponding author)
8. **Lin YC**, Liu HE, Wang CH, Wang HM, Yang TS, Liao CT, Chen JS: Clinical benefit response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV). *Anticancer Research* 19: 5615-5620, 1999.(SCI)
9. Yu PC, **Lin YC**, Chen HM, Chen MF. Malignant phyllodes tumor of breast metastasizing to the pancreas: case report. *Chang Gung Med J*, 23: 503-507, 2000.
10. Yang TS, **Lin YC**, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. *Cancer*, 89:750-756 ,

2000.(SCI)

11. **Lin YC**, Chang HK, Wang CH, Chen JS, Liaw CC. Single-agent docetaxel in Metastatic breast cancer patients pre-treated with anthracyclin and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. *Anti-Cancer Drugs*, 11: 617-621, 2000.(SCI)

12. Chen JS, **Lin YC**, Jan YY, Liao CT. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. *Anti-Cancer Drugs*, 12: 339-343, 2001. (SCI)

13. **Lin YC**, Chen JS, Wang CH, Wang HM, Chang HK, Liao CT, Yang TS, Liaw.CC. Weekly high-dose 5-fluorouracil(5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer. *Jap J Clin Oncol*, 31; 605-609, 2001. (SCI)

14. Liaw CC, Wang CH, Chang HK, Yeh KY, Haung JS, **Lin YC**. Gender discrepancy observed between chemotherapy-induced emesis and hiccups. *Support Care Cancer*(6) 435-41, 2001.(SCI)

15. Yang TS, Hsu KC, Wang HM, **Lin YC**. Phase II study of a weekly 8-Hour 5-fluorouracil and leucovorin infusion for patient with advanced colorectal cancer:

Dose adjust according to its toxicity. *Jap J Clin Oncol*, 31; 610-615, 2001. (SCI)

16. **Lin YC**, Wu Chou YH, Liao I-C, Cheng AJ. The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer Patients as an adjunct to serum tumor markers. *Cancer Letter*,191: 93-99, 2003(SCI: IF=3.504; Oncology 51/141)

17. **Lin YC**, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, Liaw IC, Cheng AJ. Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. *Cancer Science*, 94:99-102, 2003 (SCI).

18. Cheung YC, Chen SC, Su MT, See LC, Hsueh S, Chang HK, **Lin YC**, Tsai CS. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy(weekly paclitaxel and epirubicin) with serial enhanced MRI. *Breast Cancer Research and Treatment*. 78:51-58, 2003. (SCI)

19. Liaw CC, Chang HK, Liao CT, Huang JS, **Lin YC**, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. *Am J Clin Oncol* 26(1) 12-15, 2003. (SCI)

20. Li KKC, Goodall J, Goding CR, Liao SK, Wang CH, **Lin YC**, Hiraga H, Nojima T, Nagashima K, Lee KAW. The melanocyte inducing factor is stably expressed in cell lines from human clear cell sarcoma. *Brit J Cancer*, 89:1072-1078, 2003. (SCI)

21. Chen JS. **Lin YC**. Liao CT. Wang CH. Liaw CC. Mitomycin C (MMC) with

- weekly 24-hour infusions of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. *Chang Gung Medical Journal*. 26(6):433-9, 2003.
22. Chen JS, Yang TS, **Lin YC**, Jan YY. A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. *Japanese Journal of Clinical Oncology*. 33(7):353-6, 2003 Jul. (SCI)
23. Sheen WC, Chen JS, Wang HM, Yang TS, Liaw CC, **Lin YC***. A modified low-dose mitoxantrone and prednisolone (MP) in patients with androgen independent prostate cancer. *Japanese Journal of Clinical Oncology*. 34(6):353-6, 2004 June. (**corresponding author**) (SCI)
24. Yang TS, Chang HK, Chen JS, **Lin YC**, Liao CT, Chang WC. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. *J Gastroenterol*. 2004;39(4):362-9. 9 (SCI)
25. Chen JS, Huang JS, Yang TS, **Lin YC**, Wang HM, Liao CT, Rau KM. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. *Anti-Cancer Drugs*, 16: 47-51, 2005. (SCI)
26. Chen SC, Chang HK, **Lin YC**, Cheung YC, Tsai CS, Leung WM, Hsueh S, Chen MF. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. *Onkologie*, 28:339-344, 2005. (SCI)
27. **Lin YC**, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF. Identifying good prognosis group of breast cancer patients with 1 to 3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (cmf) chemotherapy. *Japanese Journal of Clinical Oncology*. 35: 514-519, 2005. (SCI)
28. Liaw CC, Wang CH, Chang HK, Wang HM, Huang JS, **Lin YC**, Chen JS. Cisplatin-related hiccups: male predominant, induction by dexamethasone, and protection against nausea and vomiting. *Journal of Pain and Symptom Management*, 30:359-366, 2005. (SCI)
29. Chen SC, Chang HK, **Lin YC**, Leung WM, Tsai CS, Cheung YC, Hsueh S, See LC and Chen MF. Prognosis of breast cancer after supraclavicular lymph node metastasis: not a distant metastasis, *Annals of Surgical Oncology* 13:1457-65, 2006. (SCI)
30. **Lin YC**, Chang HK, Chen JS, Wang HM, Yang TS and Liaw CC. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: A final analysis. *Japanese Journal of Clinical Oncology*. 37: 23-29, 2007. (SCI)

31. Lu CH, **Lin YC***, Chang HK. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital. *Chang Gung Medical Journal*. 2007; 30: 18-25.
(corresponding author)
32. Lin C-Y, Tsai IF, Ho YP, Huang CT, **Lin YC**, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS. Endotoxemia contributes to the immune paralysis in patients with liver cirrhosis short title: immune paralysis in cirrhosis and endotoxemia. *J Hepato*, 2007, 46: 816-26.(SCI)
33. **Y-C Lin**, H-K Chang, W-C Shen, J-S Chen, H-M Wang. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naïve patients with metastatic breast cancer. *Anti-Cancer Drug*, 2007;18: 1213-1219. (SCI)
34. I-F Tsai, C-Y Lin, C-T Huang, **Y-C Lin**, C-M Yang, Y-C Lin, C-H Liao. Modulation of human monocyte-derived dendritic cells maturation by a soluble quanylate cyclase activator, YC-1, in a cyclic nucleotide independent manner. *International immunopharm*, 2007, 7: 1299-310. (SCI)
35. Chang JT, Chen CJ, **Lin YC**, Chen YC, Lin CY, Cheng AJ. Health-related quality of life and patient satisfaction after treatment for breast cancer in northern Taiwan. *Inter J Radia Oncol, Bio, Phy*. 69(1):49-53, 2007.(SCI)
36. SC Chen, HK Chang, **YC Lin**, S Hsueh, YC Cheung, WM Leung, CS Tsai, YF Lo, HP Tsai, SC Shen, MF Chen. High pathologic complete response in her 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. *Jpn J Clin Oncol* 2008;38(2)99-105. (SCI)
37. Z Chu, JS Chen, CT Liao, HM Wang, **YC Lin**, MH Yang, PM Chen, ER Gardner, WD Figg, A Sparreboom. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. *Anti-Cancer Drugs*. 19(3):275-81, 2008. (SCI)
38. CH Yang, WC Lin, CK Chuang, YC Chang, ST Pang, **YC Lin**, TT Kuo, JJ Hsieh, JW Chang. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. *British Journal of Dermatology*. 158(3):592-6, 2008. (SCI)
39. JS Chen, KM Rau, YY Chen, JS Huang, TS Yang, **YC Lin**, CT Liao, KD Lee, YC Su, RH Kao. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemo-naïve patients with advanced gastric cancer. *Cancer Chemother Pharmacol*. 63(5):819-25, 2009. (SCI)
40. HC Hsu, HK Chang; **YC Lin**, S Hsueh, JSh Chen; TS Yang, HM Wang, WC Shen.

The Role of HER2 in Metastatic Breast Cancer Treated with a Combination of Taxanes and Cisplatin. *Chang Gung Medical Journal* , 2009; 32: 33-41.

41. **YC Lin**, LY Chang, C-T Huang, HM Peng, A Dutta, TC Chen, CT Yeh, CY Lin.

Effector/memory but not naïve regulatory T cells are responsible for the loss of concomitant tumor immunity. *J Immunology*, 182: 6095-6104, 2009(SCI)

42. YW Hsiao, **YC Lin**, R Y Hui, C-H Yang. Fulminant Acneiform Eruptions After Administration of Dovitinib in a Patient With Renal Cell Carcinoma. *J Clin Oncol*, 2011 20;29(12):e340-1. (SCI,)

43. Chen JS, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, Hsu HC, **Lin YC**, Wang HM; A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. *Gastric Cancer*. 2012 Jan;15(1):49-55. (SCI)

44. Jane SW, Chen SL, Wilkie DJ, **Lin YC**, Foreman Wang SY, Beaton RD, Fan JY, Lu MY, Wang YY, Lin YH, Liao MN. Effects of Massage on Pain, Mood Status, Relaxation, and Sleep in Taiwanese Patients with Metastatic Bone Pain: A Randomized Clinical Trial. *Pain*, 2011 Oct;152(10):2432-42. (SCI):. 2432-2422.

45. Su PJ, Chen JS, Liaw CC, Chang HK, Wang HM, Yang TS, **Lin YC**, Liau CT, Yang HY, Yeh KY, Ho MM, Chang NJ, Wang CH, Chang JW., Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma. *Chang Gung Med J*, 2011. **34**(5): p.478-86.

46. Shen SC, Liao CH, Lo YF, Tsai HP, Kuo WL, Yu CC, Chao TC, Chen MF, Chang HK, **Lin YC**, Shen WC, Ueng SH, Lee LY, Hsueh S, Huang YT, Chen SC. Favorable Outcome of Secondary Axillary Dissection in Breast Cancer Patients with Axillary Nodal Relapse. *Ann Surg Oncol*, 2012 Apr;19(4):1122-8.

47. Chen CC, Lin WC, Kong MS, Shi HN, Walker WA, Lin CY, Huang CT, **Lin YC**, Jung SM, Lin TY. Oral inoculation of probiotics *Lactobacillus acidophilus* NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. *Br J Nutr*, 2011: p. 1-12.

48. Chang LY, **Lin YC**, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, Day YJ, Chen TC, Yeh CT, Lin CY. Tumor-derived chemokine CCL5 enhances TGF- β mediated killing of CD8⁺ T cells in colon cancer by T regulatory cells. *Cancer Research* 2012 Mar 1;72(5):1092-102.

49. **Lin YC**, Mahalingam J, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Chiu CT, Lin CY. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. *Int J Cancer*. 2012 Aug 21. (Epub)

50. Mahalingam J, **Lin YC**, Chiang JM, Su PJ, Fang JH, Chu YY, Huang CT, Chiu CT, Lin CY. LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with progression of colorectal cancer. *Clin Cancer Res*. 2012 Aug 8.(Epub)
51. Huang WK, Chang JW, See LC, Tu HT, Chen JS, Liaw CC, **Lin YC**, Yang TS. Higher rate of colorectal cancer among patients with pyogenic liver abscess with *Klebsiella pneumoniae* than those without: an 11-year follow-up study. *Colorectal Dis*. 2012 Jul 7. (Epub)
52. Chang LY, **Lin YC**, Kang CW, Hsu CY, Chu YY, Huang CT, Day YJ, Chen TC, Yeh CT, Lin CY. The Indispensable Role of CCR5 for In Vivo Suppressor Function of Tumor-Derived CD103+ Effector/Memory Regulatory T Cells. *J Immunol*. 2012 Jul 15;189(2):567-74.
53. Cheng CY, **Lin YC**, Chen JS, Chen CH, Deng ST. Cisplatin-induced acute hyponatremia leading to a seizure and coma: a case report. *Chang Gung Med J*. 2011;34(6 Suppl):48-51.
54. Hou MM, Huang SF, Kuo HP, Yang CT, Tsai YH, Yu CT, Lin HC, Chen CH, Wang CL, Chung FT, Hsieh JJ, Hsu T, Cheng HY, Ou LY, Wang HM, **Lin YC**, Chang NJ, Chang JW. Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations. *Anticancer Res*. 2012 Mar;32(3):1107-12.
55. Hung YS, Wu JH, Chang H, Wang PN, Kao CY, Wang HM, Liao CT, Chen JS, **Lin YC**, Su PJ, et al.: Characteristics of Patients With Hematologic Malignancies Who Received Palliative Care Consultation Services in a Medical Center. *Am J Hosp Palliat Care* 2013.
56. Huang SB, Wang SS, Hsieh CH, **Lin YC**, Lai CS, Wu MH: An integrated microfluidic cell culture system for high-throughput perfusion three-dimensional cell culture-based assays: effect of cell culture model on the results of chemosensitivity assays. *Lab Chip* 2013, 13:1133-1143.
57. Dutta A, Miaw SC, Yu JS, Chen TC, Lin CY, **Lin YC**, Chang CS, He YC, Chuang SH, Yen MI, et al.: Altered T-bet Dominance in IFN-gamma-Decoupled CD4+ T Cells with Attenuated Cytokine Storm and Preserved Memory in Influenza. *J Immunol* 2013.
58. Chou WC, Hung YS, Kao CY, Su PJ, Hsieh CH, Chen JS, Liao CT, **Lin YC**, Liaw CC, Wang HM: Impact of palliative care consultative service on disease awareness for patients with terminal cancer. *Support Care Cancer* 2013.
59. Ueng SH, Chen SC, Chang YS, Hsueh S, **Lin YC**, Chien HP, Lo YF, Shen SC, Hsueh C: Phosphorylated mTOR expression correlates with poor outcome in

- early-stage triple negative breast carcinomas. *Int J Clin Exp Pathol* 2012, 5:806-813.
60. Liao MN, Chen SC, Chen SC, **Lin YC**, Hsu YH, Hung HC, Wang CH, Chen MF, Jane SW: Changes and predictors of unmet supportive care needs in Taiwanese women with newly diagnosed breast cancer. *Oncol Nurs Forum* 2012, 39:E380-389.
61. Huang WK, Liaw CC, Pang ST, Chuang CK, Chiang YJ, Wu CT, Chang YH, Wang HM, **Lin YC**, Hsieh JJ, et al.: Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital. *Chang Gung Med J* 2012, 35:402-407.
62. Hsieh CH, Hsu CL, Wang CH, Liaw CC, Chen JS, Chang HK, Yang TS, Chang JW, **Lin YC**, Liao CT, et al.: Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma. *Biomed J* 2013, 36:229-236.
63. Hsu HC, Chou WC, Shen WC, Wu CE, Chen JS, Liao CT, **Lin YC**, Yang TS: Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer. *Anticancer Res* 2013, 33:3317-3325.
64. Huang WK, **Lin YC**, Chiou MJ, Yang TS, Chang JW, Yu KH, Kuo CF, See LC: Pyogenic liver abscess as a warning sign for primary liver cancer: a nationwide population-based study. *Asian Pac J Cancer Prev* 2013, 14:4727-4731.
65. Kao CY, Wang HM, Tang SC, Huang KG, Jaing TH, Liu CY, Liu KH, Shen WC, Wu JH, Hung YS, Hsu HC, Chen JS, Liao CT, **Lin YC**, Su PJ, Hsieh CH, Chou WC.: Predictive Factors For Do-Not-Resuscitate Designation Among Terminally Ill Cancer Patients Receiving Care From a Palliative Care Consultation Service. *J Pain Symptom Manage* 2013.
66. Liao MN, Chen SC, Chen SC, **Lin YC**, Chen MF, Wang CH, Hsu YH, Hung HC, Jane SW: Change and predictors of symptom distress in breast cancer patients following the first 4 months after diagnosis. *J Formos Med Assoc* 2013.
67. Liao MN, Chen SC, **Lin YC**, Chen MF, Wang CH, Jane SW: Education and psychological support meet the supportive care needs of Taiwanese women three months after surgery for newly diagnosed breast cancer: A non-randomised quasi-experimental study. *Int J Nurs Stud* 2013.
68. Wu CE, Hsieh CH, Chang CJ, Yeh JT, Kuo TT, Yang CH, Lo YF, Lin KJ, **Lin YC**, Chang JW: Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy. *J Formos Med Assoc* 2013.
69. Wu CE, **Lin YC**, Hong JH, Chuang CK, Pang ST, Liaw CC: Prognostic value of

complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy. *Anticancer Res* 2013, 33:2605-2610.

International Conference Presentations:

1. Endometroid carcinoma of the prostate: A clinically distinct subtype of prostate cancer. 31st Annual meeting of American Society of Clinical Oncology, Los Angeles, May 1995.
2. Primary concurrent chemoradiotherapy for locally advanced esophageal cancer. 3th Asia-Pacific Cancer Conference(APCC), Penang, Malaysia, Nov, 1995.
3. Weekly high dose 24-hour infusion 5-FU and Leucovorin in patients with metastatic pancreatic-biliary tract cancer, The annual meeting of Chinese Oncology Society, Taipei, May 1997.
4. Clinical response, Quality of Life and Clinic Benefit in patients with metastatic gastric cancer treated with weekly high dose 24-hour infusion 5-FU and Leucovorin. 5th Sino-Japan symposium for cancer treatment: gastric cancer from basic to clinic. Taipei, Oct. 1997.
5. Weekly high dose 24-hour infusion 5-FU and Leucovorin in patients with metastatic biliary tract cancer. 4th Asia-Pacific Cancer Conference(APCC), Hong Kong, Nov, 1997.
6. Validation of different clinical response criteria for gastric cancer with weekly high-dose 5-fluorouracil and leucovorin 24-hr continuous therapy. 34th annual meeting of American Society of Clinical Oncology, Los Angeles, May 1998.
7. The preliminary result of adjuvant chemotherapy with escalated dose of cyclophosphamide, epirubicin and fluorouracil (CEF) in patients with breast cancer with axillary lymph node metastases more than 3 and historical control with low dose CEF. 2nd Terry Fox and Chang Gung Memorial Hospital International Cancer Symposium on Breast cancer. Taipei, Oct. 1998.
8. Cisplatin, tegafur, & leucovorin: An effective, nontoxic, and outpatient neoadjuvant chemotherapy for squamous cell carcinoma of the head and neck. 35th annual

- meeting of American Society of Clinical Oncology, Atlanta, May 1999.
9. Mitomycin (MMC) with weekly 24-hour high-dose 5-fluorouracil (5-FU) and leucovorin (LV) on patients with advanced gastric cancer - preliminary analysis. 4th Terry Fox and Chang Gung Memorial Hospital International Cancer Symposium on Breast cancer. Taipei, Oct. 2000.
 10. A modified low-dose mitoxantrone and prednisolone (MP) in patients with androgen independent prostate cancer (AIPCa). In 5th Annular meeting of Asian Clinical Oncology Society. Taipei, April 2001.
 11. Multiple immunization with granulocyte-macrophage colony stimulating factor(GM-CSF) modified tumor vaccine delayed tumor growth on mouse malignant melanoma. In 5th Annular meeting of Asian Clinical Oncology Society. Taipei, April 2001.
 12. Prognostic factors of breast cancer patients with 1 to 3 lymph node metastases after adjuvant chemotherapy. In 11th European Cancer Conference. Lisbon, Oct, 2001.
 13. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: preliminary result. In 39th annual meeting of American Society of Clinical Oncology, Chigago, June 2003.
 14. The Inhibition of Tumor Growth by Thalidomide is Association with Decreased Effector/Memory Regulatory T Cells. In International regulatory T cell symposium, Beijing, 2008.
 15. The role of effective Treg cell in murine concomitant tumor immunity model. In Internation regulatory T cell symposium, Beijing 2008.
 16. Effector/Memory Regulatory T cells Lead to the Loss of Concomitant Tumor Immunity. In Keystone symposium, 2008.

Book Chapter

Bladder cancer, **Yung-Chang Lin**, Shi-Ming Tu. In: Medical Oncology: a comprehensive review. 2nd edition, Editor: Richard Pazdur. Publisher: PRR, Inc. New York, 1996.